Pharmacokinetics and Bioavailability of an Integrase and Novel Pharmacoenhancer-Containing Single-Tablet Fixed-Dose Combination Regimen for the Treatment of H IVGERMAN, Polina; WARREN, David; WEST, Steve et al.Journal of acquired immune deficiency syndromes (1999). 2010, Vol 55, Num 3, pp 323-329, issn 1525-4135, 7 p.Article

Pharmacokinetic Interaction of Ritonavir-Boosted Elvitegravir and MaravirocRAMANATHAN, Srinivasan; ABEL, Samantha; TWEEDY, Sarah et al.Journal of acquired immune deficiency syndromes (1999). 2010, Vol 53, Num 2, pp 209-214, issn 1525-4135, 6 p.Article

Effect of Ritonavir-Boosted Tipranavir or Darunavir on the Steady-State Pharmacokinetics of ElvitegravirMATHIAS, Anita A; HINKLE, John; GONG SHEN et al.Journal of acquired immune deficiency syndromes (1999). 2008, Vol 49, Num 2, pp 156-162, issn 1525-4135, 7 p.Article

Pharmacologie des inhibiteurs de l'intégrase du VIH = Clinical pharmacology of HIV integrase inhibitorsSOLAS-CHESNEAU, C; QUARANTA, S; LACARELLE, B et al.Virologie (Montrouge). 2009, Vol 13, Num MAI, issn 1267-8694, S25-S34, NSArticle

Clinical Pharmacokinetic and Pharmacodynamic Profile of the HIV Integrase Inhibitor ElvitegravirRAMANATHAN, Srinivasan; MATHIAS, Anita A; GERMAN, Polina et al.Clinical pharmacokinetics. 2011, Vol 50, Num 4, pp 229-244, issn 0312-5963, 16 p.Article

Next-Generation Integrase Inhibitors: Where to After Raltegravir?KARMON, Sharon L.Drugs (Basel). 2013, Vol 73, Num 3, pp 213-228, issn 0012-6667, 16 p.Article

A Randomized Phase 3 Study Comparing Once-Daily Elvitegravir With Twice-Daily Raltegravir in Treatment-Experienced Subjects With HIV-1 infection: 96-Week ResultsELION, Richard; MOLINA, Jean-Michel; CHUCK, Steven L et al.Journal of acquired immune deficiency syndromes (1999). 2013, Vol 63, Num 4, pp 494-497, issn 1525-4135, 4 p.Article

Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infectionGARRIDO, Carolina; GERETTI, Anna Maria; ZAHONERO, Natalia et al.Journal of antimicrobial chemotherapy (Print). 2010, Vol 65, Num 2, pp 320-326, issn 0305-7453, 7 p.Article

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 StudyCASTAGNA, Antonella; MAGGIOLO, Franco; DOROANA, Manuela et al.The Journal of infectious diseases. 2014, Vol 210, Num 3, pp 354-362, issn 0022-1899, 9 p.Article

Dolutegravir: A New Integrase Strand Transfer Inhibitor for the Treatment of HIVSHAH, Bhavik M; SCHAFER, Jason J; DESIMONE, Joseph A et al.Pharmacotherapy. 2014, Vol 34, Num 5, pp 506-520, issn 0277-0008, 15 p.Article

A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 96 ResultsROCKSTROH, Jürgen K; DEJESUS, Edwin; FORDYCE, Marshall W et al.Journal of acquired immune deficiency syndromes (1999). 2013, Vol 62, Num 5, pp 483-486, issn 1525-4135, 4 p.Article

Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143METIFIOT, Mathieu; VANDEGRAAFF, Nick; MADDALI, Kasthuraiah et al.AIDS (London). 2011, Vol 25, Num 9, pp 1175-1178, issn 0269-9370, 4 p.Article

Integrase Inhibitors: A Novel Class of Antiretroviral AgentsSCHAFER, Jason J; SQUIRES, Kathleen E.The Annals of pharmacotherapy. 2010, Vol 44, Num 1, pp 145-156, issn 1060-0280, 12 p.Article

Activity of Elvitegravir, a Once-Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose-Ranging Clinical TrialZOLOPA, Andrew R; BERGER, Daniel S; LAMPIRIS, Harry et al.The Journal of infectious diseases. 2010, Vol 201, Num 6, pp 814-822, issn 0022-1899, 9 p.Article

Pharmacokinetics and Safety of Boosted Elvitegravir in Subjects with Hepatic ImpairmentCUSTODIO, Joseph M; RHEE, Martin; GONG SHEN et al.Antimicrobial agents and chemotherapy. 2014, Vol 58, Num 5, pp 2564-2569, issn 0066-4804, 6 p.Article

Investigation of the Interactions between Methadone and Elvitegravir-Cobicistat in Subjects Receiving Chronic Methadone MaintenanceBRUCE, R. Douglas; WINKLE, P; CUSTODIO, J. M et al.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 12, pp 6154-6157, issn 0066-4804, 4 p.Article

Broad Phenotypic Cross-Resistance to Elvitegravir in HIV-Infected Patients Failing on Raltegravir-Containing RegimensGARRIDO, Carolina; VILLACIAN, Jorge; ZAHONERO, Natalia et al.Antimicrobial agents and chemotherapy. 2012, Vol 56, Num 6, pp 2873-2878, issn 0066-4804, 6 p.Article

Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirineRAMANATHAN, Srinivasan; KAKUDA, Thomas N; MACK, Rebecca et al.Antiviral therapy (London). 2008, Vol 13, Num 8, pp 1011-1017, issn 1359-6535, 7 p.Article

Drug safety profile of integrase strand transfer inhibitorsDEL MAR GUTIERREZ, Maria; MATEO, Maria Gracia; VIDAL, Francesc et al.Expert opinion on drug safety. 2014, Vol 13, Num 4, pp 431-445, issn 1474-0338, 15 p.Article

Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase InhibitorsGOETHALS, Olivia; CLAYTON, Reginald; MEERSSEMAN, Geert et al.Journal of virology. 2008, Vol 82, Num 21, pp 10366-10374, issn 0022-538X, 9 p.Article

Structure-based predictors of resistance to the HIV-1 integrase inhibitor ElvitegravirMASSO, Majid; CHUANG, Grace; HAO, Kate et al.Antiviral research. 2014, Vol 106, pp 5-12, issn 0166-3542, 8 p.Article

Est-il possible qu'il n'y aura jamais de résistance contre le dolutégravir si ce médicament est utilisé en première ligne ? = What if HIV were unable to develop resistance against dolutegravir as first line therapeutic agent?WAINBERG, M. A; MESPLEDE, T; RAFFI, F et al.Journal des anti-infectieux (Print). 2014, Vol 16, Num 2, pp 44-49, issn 2210-6545, 6 p.Article

HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assaysBAR-MAGEN, Tamara; DONAHUE, Daniel A; MCDONOUGH, Emily I et al.AIDS (London). 2010, Vol 24, Num 14, pp 2171-2179, issn 0269-9370, 9 p.Article

Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA ComplexesHIGHTOWER, Kendra E; WANG, Ruolan; SEKI, Takahiro et al.Antimicrobial agents and chemotherapy. 2011, Vol 55, Num 10, pp 4552-4559, issn 0066-4804, 8 p.Article

In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4MARGOT, Nicolas A; HLUHANICH, Rebecca M; JONES, Gregg S et al.Antiviral research. 2012, Vol 93, Num 2, pp 288-296, issn 0166-3542, 9 p.Article